IL325352A - אנאלוגי אינקרטין ושימושם - Google Patents

אנאלוגי אינקרטין ושימושם

Info

Publication number
IL325352A
IL325352A IL325352A IL32535225A IL325352A IL 325352 A IL325352 A IL 325352A IL 325352 A IL325352 A IL 325352A IL 32535225 A IL32535225 A IL 32535225A IL 325352 A IL325352 A IL 325352A
Authority
IL
Israel
Prior art keywords
incretin analogs
incretin
analogs
Prior art date
Application number
IL325352A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL325352A publication Critical patent/IL325352A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Details Of Garments (AREA)
  • Medicinal Preparation (AREA)
IL325352A 2017-12-21 2025-12-15 אנאלוגי אינקרטין ושימושם IL325352A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608644P 2017-12-21 2017-12-21
PCT/US2018/065605 WO2019125929A1 (en) 2017-12-21 2018-12-14 Incretin analogs and uses thereof

Publications (1)

Publication Number Publication Date
IL325352A true IL325352A (he) 2026-02-01

Family

ID=65003515

Family Applications (2)

Application Number Title Priority Date Filing Date
IL275469A IL275469B1 (he) 2017-12-21 2020-06-17 אנאלוגי אינקרטין ושימושם
IL325352A IL325352A (he) 2017-12-21 2025-12-15 אנאלוגי אינקרטין ושימושם

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL275469A IL275469B1 (he) 2017-12-21 2020-06-17 אנאלוגי אינקרטין ושימושם

Country Status (26)

Country Link
US (2) US11834486B2 (he)
EP (1) EP3727425A1 (he)
JP (2) JP6987993B2 (he)
KR (1) KR102440323B1 (he)
CN (1) CN111511387A (he)
AR (1) AR113487A1 (he)
AU (1) AU2018388895B2 (he)
BR (1) BR112020010410A2 (he)
CA (1) CA3084004C (he)
CL (1) CL2020001636A1 (he)
CO (1) CO2020006253A2 (he)
CR (1) CR20200256A (he)
DO (1) DOP2020000124A (he)
EA (1) EA202091284A1 (he)
EC (1) ECSP20032306A (he)
IL (2) IL275469B1 (he)
JO (1) JOP20200136A1 (he)
MA (1) MA51287A (he)
MX (2) MX2020006547A (he)
MY (1) MY199545A (he)
PE (1) PE20200926A1 (he)
PH (1) PH12020551024A1 (he)
SG (1) SG11202004359YA (he)
TW (2) TWI767095B (he)
UA (1) UA127589C2 (he)
WO (1) WO2019125929A1 (he)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
KR20210031533A (ko) 2018-07-23 2021-03-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
MY201700A (en) 2019-08-19 2024-03-13 Lilly Co Eli Methods of making incretin analogs
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US20230265151A1 (en) * 2020-01-23 2023-08-24 Eli Lilly And Company Gip/glp1 co-agonist compounds
EP4183419A4 (en) * 2020-07-17 2025-04-02 Hanmi Pharm. Co., Ltd. THERAPEUTIC USE OF A COMBINATION WITH A LONG-ACTING TRIPLE AGONIST CONJUGATE OR TRIPLE AGONIST
CA3187742A1 (en) * 2020-08-14 2022-02-17 Seungjae Baek Pharmaceutical composition comprising long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
JP2023550594A (ja) 2020-10-30 2023-12-04 ノヴォ ノルディスク アー/エス Glp-1、gip、およびグルカゴン受容体三重作動薬
TW202423476A (zh) 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CN117062618B (zh) * 2021-05-26 2026-01-02 联邦生物科技(珠海横琴)有限公司 多激动剂及其应用
CN115572326B (zh) * 2021-06-21 2025-01-10 广东东阳光药业股份有限公司 Glp-1、gcg和gip受体的三重激动剂
JP2024524180A (ja) 2021-06-23 2024-07-05 イーライ リリー アンド カンパニー インクレチン類似体の使用方法及びインクレチン類似体を含む組成物
WO2023088140A1 (zh) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 订合肽及其应用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
KR20250075689A (ko) * 2022-09-28 2025-05-28 선샤인 레이크 파르마 컴퍼니 리미티드 Glp-1/gcg/gip 삼중-수용체 작용제 및 이의 용도
KR20250141711A (ko) 2022-12-30 2025-09-29 알지파마 에이에스 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
CN121002051A (zh) * 2023-04-11 2025-11-21 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
CN120349393A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种三激动剂化合物
CN120329412A (zh) * 2023-11-06 2025-07-18 成都奥达生物科技有限公司 一种三激动剂化合物
CN119241684B (zh) * 2024-11-22 2025-02-25 徐州医科大学 一种肠促胰岛素类似物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021146B1 (ru) 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
US10093713B2 (en) * 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
MX369770B (es) * 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR104932A1 (es) * 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
HUE059737T2 (hu) 2015-12-31 2022-12-28 Hanmi Pharm Ind Co Ltd Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor
EP3217027A1 (de) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Breites einlageelement zum einfassen einer ankerstange
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
AR113487A1 (es) 2020-05-06
MX2020006547A (es) 2020-12-09
MA51287A (fr) 2021-03-31
CA3084004A1 (en) 2019-06-27
AU2018388895B2 (en) 2020-12-24
US11834486B2 (en) 2023-12-05
TWI810937B (zh) 2023-08-01
EP3727425A1 (en) 2020-10-28
JOP20200136A1 (ar) 2022-10-30
US20210221865A1 (en) 2021-07-22
DOP2020000124A (es) 2020-08-31
SG11202004359YA (en) 2020-06-29
PH12020551024A1 (en) 2021-05-31
US20240190936A1 (en) 2024-06-13
JP6987993B2 (ja) 2022-01-05
TW201938187A (zh) 2019-10-01
UA127589C2 (uk) 2023-10-25
KR102440323B1 (ko) 2022-09-05
EA202091284A1 (ru) 2020-09-08
ECSP20032306A (es) 2020-07-31
PE20200926A1 (es) 2020-09-14
MX2025003745A (es) 2025-05-02
KR20200088418A (ko) 2020-07-22
CR20200256A (es) 2020-07-12
AU2018388895A1 (en) 2020-06-04
CO2020006253A2 (es) 2020-05-29
NZ765268A (en) 2024-07-05
TWI767095B (zh) 2022-06-11
BR112020010410A2 (pt) 2020-11-24
CN111511387A (zh) 2020-08-07
JP2022043082A (ja) 2022-03-15
CL2020001636A1 (es) 2020-10-16
MY199545A (en) 2023-11-06
TW202233227A (zh) 2022-09-01
CA3084004C (en) 2023-06-20
WO2019125929A1 (en) 2019-06-27
IL275469B1 (he) 2026-01-01
JP2021506825A (ja) 2021-02-22
IL275469A (he) 2020-08-31

Similar Documents

Publication Publication Date Title
IL325353A (he) אנאלוגי אינקרטין ושימושם
IL325352A (he) אנאלוגי אינקרטין ושימושם
IL273236A (he) תרכובות פירזולופירימידינונים ושימושים שלהם
IL265922A (he) מעכבי tyk2 ושימושים בהם
IL266109A (he) מעכבי tyk2 ושימושים בהם
IL255577B (he) חומרים קושרי- tigit ושימושים בהם
IL253433A0 (he) חומרים קושרי- tnfrsf ושימושים בהם
PL3508580T3 (pl) Nowy promotor i jego zastosowanie
PL3250692T3 (pl) Promotor i jego zastosowania
IL254977B (he) תצמידים ביולוגים ושימושים בהם
IL254089A0 (he) דסאאצטוקסיטובוליזין h ואנלוגים שלו
IL265531A (he) תיאנואורצילים מותמרים ציקלית–n3 ושימוש בהם
IL248424B (he) חומרים מגיני עצבים ושימושים בהם
GB201612150D0 (en) Modified peptide
IL254241A0 (he) Etv2 ושימושים בו
TWI561532B (en) Teicoplanin analogs and uses thereof
IL251289A0 (he) נגזרות פפטיד חדשות ושימוש בהן
IL251588A0 (he) שיטות ותכשירים להגדלת העוצמה של חומרים נגד פטריות
SG11201610918RA (en) Peptides and uses thereof
GB201707846D0 (en) Use
HK40029619A (en) Incretin analogs and uses thereof
IL248576A0 (he) תכשיר נגד כינים ושימושיו
PH32016000058S1 (en) Chair (gregoria)
PH32016000066S1 (en) Chair (basilisa)
GB201504211D0 (en) Use of peptides